Navigation Links
Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
Date:2/2/2009

WALTHAM, Mass., Feb. 2 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at the BIO CEO and Investor Conference on Monday, February 9th, 2009 at 11:30 a.m. EST at the Waldorf-Astoria Hotel, 301 Park Avenue, New York, NY.

A live audio webcast of the presentation will be available via Repligen's website at www.repligen.com and will be archived for 30 days following the presentation.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, pla
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... GliaCure, a privately-held biotechnology company focused ... and neuropsychiatric disorders based on glial targets, announced ... in a Phase 1b clinical trial of its ... a potential disease-modifying treatment. GliaCure,s innovative approach to ... both promotes the clearance of amyloid and stimulates ...
(Date:5/4/2015)... , May 4, 2015  Tikcro Technologies Ltd. ... annual report on Form 20-F for the fiscal year ... Exchange Commission ("SEC"). The annual report on Form 20-F ... of antibodies in the area of cancer immune checkpoints. ... qualities of high specificity and binding in targeting certain ...
(Date:5/4/2015)... 2015  Traverse Biosciences announced today that it ... agreement (CRADA) with Aratana Therapeutics Inc. (NASDAQ: ... for the treatment and control of periodontal disease ... Biosciences has also granted Aratana an exclusive option ... of periodontal disease in companion animals, inclusive of ...
(Date:5/4/2015)... /PRNewswire/ - Fluorinov Pharma (Fluorinov), a FACIT portfolio ... Dr. Roger J Garceau, to its Board of ... matters including corporate development and clinical strategy, his ... regulatory expertise as Fluorinov transitions to clinical development.  ... of pharmaceutical development experience to Fluorinov and most ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3
... Calif., March 31 Sigma-Aldrich (Nasdaq: ... high quality services and oligonucleotides to Gene Oracle, an ... the agreement, Sigma-Aldrich will be the exclusive supplier of ... will engage in co-marketing efforts to promote the GeneIOS ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced ... the company,s board of directors. Dr. Hutson retired ... in various research and leadership positions with that company, ... Research and Development and director of Pfizer,s pharmaceutical R&D ...
... MYL ) today announced that Matrix Laboratories ... 71.2% controlling interest, has received the first tentative approval ... the President,s Emergency Plan for AIDS Relief (PEPFAR) for ... Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg.Mylan Vice Chairman ...
Cached Biology Technology:Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 2Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 3Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors 2Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors 3Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors 4Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R) 2
(Date:4/27/2015)... , April 27, 2015  For more than four ... show has been the premier worldwide event for the ... is a must-attend event for any local, national, or ... the emerging commercial markets and current applications of unmanned ... of this projected $48 billion industry, and how it ...
(Date:4/27/2015)... Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... pre-order customers the first week of May, 2015 and ... of May. Gino Pereira , ... for the company as Wocket® enters the consumer market. ...
(Date:4/27/2015)... Fla. , Apr. 27, 2015 Profile ... access control and security systems is pleased to announce ... company as a consultant and member of its scientific ... is widely known as a thought leader in technology-enhanced ... Learning Technology Group, and has published studies and books ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... German . To further enhance ... Forschungsgemeinschaft (DFG, German Research Foundation) has established twelve new ... DFG,s relevant Grants Committee in Bonn. The new Research ... training at a highly specialised level within a structured ...
... can incite the body to attack its own nerve ... both viral and nerve proteins. The dual-receptor observation suggests ... be triggered in susceptible young adults afflicted with multiple ... Immunology scientists Qingyong "John" Ji, Antoine Perchellet, and Joan ...
... University of Illinois at Chicago have discovered that an ... down and inhibiting the formation of excess scar tissue ... this week in Nature Cell Biology . ... "recruited" to the wound site that rapidly produce extracellular ...
Cached Biology News:DFG establishes 12 new research training groups 2DFG establishes 12 new research training groups 3DFG establishes 12 new research training groups 4DFG establishes 12 new research training groups 5DFG establishes 12 new research training groups 6Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 2Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 3Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 4Researchers discover mechanism that limits scar formation 2
Request Info...
... The Luminex® 200 System with ... for developing single and multi-analyte assays ... contains the new, powerful user friendly ... user can design specific templates for ...
Recombinant Rat Leptin, CF...
... culture chambered coverslips are convenient ... staining and imaging. The chambered ... with standard optical-quality coverslips and ... to use. Preassembled CultureWell systems ...
Biology Products: